Vectorite Biomedical

Vectorite Biomedical EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is 15.65 %. In the previous year, Year-over-Year EBITDA Growth was -61.00 % — a change of -125.66% (higher).

EBITDA Growth YoY

15.65 %

YoY

-125.66%

Last updated:

Year-over-Year EBITDA Growth of Vectorite Biomedical is 2025 15.65 % . Year-over-Year EBITDA Growth of Vectorite Biomedical was 2024 -61.00 % . It decreases by -125.66% higher compared to the previous year.

The Vectorite Biomedical EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-21.57 TWD
Jan 1, 2019
-36.73 TWD
Jan 1, 2020
42.80 TWD
Jan 1, 2021
32.58 TWD
Jan 1, 2022
187.73 TWD
Jan 1, 2023
-152.83 TWD
Jan 1, 2024
-61.00 TWD
Jan 1, 2025
15.65 TWD
The Vectorite Biomedical EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
15.65 %-125.66%
-61.00 %-60.08%
-152.83 %-181.41%
187.73 %+476.25%
32.58 %-23.89%
42.80 %-216.54%
-36.73 %+70.27%
-21.57 %-202.03%
21.14 %+142.29%
8.73 %-107.00%
-124.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

Year-over-Year EBITDA Growth of Vectorite Biomedical is 15.65 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Vectorite Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Vectorite Biomedical

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Vectorite Biomedical